Statistics from Altmetric.com
Some experiences with intra-articular (IA) infliximab treatment in patients with refractory monoarthritis have been reported, even though these studies have important limitations including small sample size and short trial duration.1–4
Aim of this study was to evaluate the efficacy and safety of IA infliximab administration in a larger cohort of patients. We studied 10 patients with rheumatoid arthritis (RA) and seven with psoriatic arthritis (PsA) with active monoarthritis lasting at least 3 months, refractory to disease-modifying antirheumatic drugs (DMARDs) and to IA glucocorticoids.5 6 DMARDs dose had to be stable for at least 6 weeks before IA injection of infliximab, …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.